Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027

Table of Contents

1            INTRODUCTION            15

1.1         OBJECTIVES OF THE STUDY      15
1.2         MARKET DEFINITION    15
1.3         MARKET SCOPE              16
1.3.1      MARKETS COVERED      16
1.3.2      YEARS COVERED FOR THE STUDY          16
1.4         CURRENCY        17
1.5         LIMITATIONS    17
1.6         STAKEHOLDERS            18

2            RESEARCH METHODOLOGY      19

2.1         RESEARCH DATA           19
2.1.1      SECONDARY SOURCES  20
2.1.1.1   KEY DATA FROM SECONDARY SOURCES             20
2.1.2      PRIMARY SOURCES        21
2.1.2.1   KEY DATA FROM PRIMARY SOURCES     22
2.1.2.2   KEY INDUSTRY INSIGHTS           22
2.2         MARKET SIZE ESTIMATION        23
2.3         MARKET BREAKDOWN AND DATA TRIANGULATION     24

3            EXECUTIVE SUMMARY  25

4            PREMIUM INSIGHTS      28

4.1         HUMAN MICROBIOME: MARKET OVERVIEW      28
4.2         HUMAN MICROBIOME MARKET, BY PRODUCT  29
4.3         EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2022)             30
4.4         HUMAN MICROBIOME MARKET, BY DISEASE     31

5            MARKET OVERVIEW      32

5.1         MARKET DYNAMICS      32
5.1.1      DRIVERS            33
5.1.1.1   INCREASED FOCUS ON HUMAN MICROBIOME THERAPY DEVELOPMENT           33
5.1.1.2   HUMAN MICROBIOME AS A VALIDATED TARGET FOR DRUG DEVELOPMENT   33
5.1.1.3   HUMAN MICROBIOME FOR EARLY DISEASE DETECTION AND DIAGNOSIS     34
5.1.2      RESTRAINTS     34
5.1.2.1   LACK OF EXPERTISE AND DETAILED RESEARCH             34
5.1.2.2   BARRIERS IN PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASE  35
5.1.3      OPPORTUNITIES            35
5.1.3.1   INVESTIGATIONAL NEW DRUG REQUIREMENTS FOR FECAL MICROBIOTA        35
5.1.3.2   INCREASING COLLABORATIONS            35
5.1.4      CHALLENGES    36
5.1.4.1   GOVERNMENT REGULATIONS  36

6            HUMAN MICROBIOME MARKET, BY PRODUCT  37

6.1         INTRODUCTION            38
6.2         PROBIOTICS     38
6.2.1      ONGOING RESEARCHES ON PROBIOTICS PROMOTING ITS CREDIBILITY IN HEALTH CLAIMS AND SAFETY     38
6.3         PREBIOTICS      40
6.3.1      DEVELOPMENT OF TARGETED PREBIOTICS TOWARDS ENHANCING GUT MICROBIOTA IS THE KEY GROWTH DRIVER FOR THIS SEGMENT             40
6.4         FOODS 41
6.4.1      RISING AWARENESS OF MICROBIOTA-TARGETED DIETS IS DRIVING
MARKET GROWTH        41
6.5         MEDICAL FOODS           42
6.5.1      USAGE OF TARGETED MICROBIOME FOR TREATING METABOLIC SYNDROME IS EXPECTED TO DRIVE THIS SEGMENT          42
6.6         DIAGNOSTIC TESTS      43
6.6.1      INCREASED CONSUMER AWARENESS ABOUT MICROBIOME-BASED TESTS, WHICH PROVIDE PREVENTATIVE HEALTH INSIGHTS TO DRIVE THIS SEGMENT  43
6.7         DRUGS 44
6.7.1      INCREASING NUMBER OF MICROBIOME-BASED DRUG PIPELINE IS THE KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT       44

7            HUMAN MICROBIOME MARKET, BY APPLICATION         47

7.1         INTRODUCTION            48
7.2         THERAPEUTICS              48
7.2.1      AVAILABILITY OF FUNDING FOR RESEARCH AND GROWING EVIDENCE FOR EFFECTIVENESS OF MICROBIOME IS FAVORING MARKET GROWTH        48
7.3         DIAGNOSTICS   50
7.3.1      INCREASING FOCUS OF BIOTECH COMPANIES ON LIFE SCIENCE RESEARCH IS SUPPORTING MARKET GROWTH        50

8            HUMAN MICROBIOME MARKET, BY DISEASE     52

8.1         INTRODUCTION            53
8.2         INFECTIOUS DISEASES 54
8.2.1      INCREASING R&D INTO TARGETED ANTI-BACTERIAL PRODUCTS WILL DRIVE MARKET GROWTH           54
8.3         INFLAMMATORY DISEASES        56
8.3.1      SIDE-EFFECTS OF IMMUNOSUPPRESSANTS HAVE PROMPTED DEMAND FOR BETTER THERAPEUTICS              56
8.4         ENDOCRINE & METABOLIC DISORDERS             58
8.4.1      GUT MICROBIOTA HAS BECOME A POTENTIAL NUTRITIONAL AND PHARMACOLOGICAL TARGET FOR OBESITY MANAGEMENT  58
8.5         CANCER             59
8.5.1      MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN THE TREATMENT OF CANCER POLYPS      59
8.6         OTHER DISEASES           61

9            HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY       62

9.1         INTRODUCTION            63
9.2         GENOMICS        63
9.2.1      SEQUENCING    65
9.2.1.1   THE DECLINING COST OF NEXT-GENERATION SEQUENCING IS DRIVING THE GROWTH OF THIS MARKET   65
9.2.2      OTHER GENOMICS TECHNOLOGIES      67
9.3         PROTEOMICS    68
9.3.1      TECHNOLOGICAL ADVANCEMENTS IN PROTEOMICS TECHNOLOGIES TO DRIVE MARKET GROWTH           68
9.4         METABOLOMICS            69
9.4.1      METABOLOMICS HAS SEVERAL ADVANTAGES OVER GENOMICS AND PROTEOMICS IN MICROBIOME RESEARCH           69

10          HUMAN MICROBIOME MARKET, BY REGION      70

10.1       INTRODUCTION            71
10.2       EUROPE             73
10.2.1    EXTENDED APPLICATIONS FOR MICROBIOME TO THERAPEUTIC AREAS TO BOOST THE ADOPTION OF MICROBIOME-BASED PRODUCTS IN EUROPE     73
10.3       NORTH AMERICA           77
10.3.1    US         79
10.3.1.1 RISING OF INVESTMENT BY NIH TO SUPPORT MICROBIOME RESEARCH IS DRIVING THE MARKET GROWTH IN THE US   79
10.3.2    CANADA            81
10.3.2.1 THE CANADIAN MICROBIOME INITIATIVE 2 IS SUPPORTING THE MARKET GROWTH IN THE COUNTRY          81
10.4       ASIA PACIFIC     84
10.4.1    INCREASING FOCUS ON MICROBIOME RESEARCH TO DRIVE
MARKET GROWTH        84
10.5       REST OF THE WORLD (ROW)    89
10.5.1    INCREASING INCIDENCE OF CANCER TO DRIVE THE DEVELOPMENT OF MICROBIOME-BASED DIAGNOSTIC TOOLS IN ROW     89

11          COMPETITIVE LANDSCAPE       92

11.1       OVERVIEW        92
11.2       COMPETITIVE LEADERSHIP MAPPING (2018)    92
11.2.1    INNOVATORS   92
11.2.2    EMERGING COMPANIES             92
11.3       COMPETITIVE SITUATION AND TRENDS            93
11.3.1    AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS            93
11.3.2    ACQUISITIONS AND MERGERS  95
11.3.3    PRODUCT LAUNCHES   96
11.3.4    EXPANSIONS     96

12          COMPANY PROFILES     97

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
12.1       ENTEROME BIOSCIENCE            97
12.2       SERES THERAPEUTICS  100
12.3       4D PHARMA PLC             102
12.4       UBIOME, INC.    104
12.5       E.I. DU PONT DE NEMOURS AND COMPANY      106
12.6       SYNLOGIC         109
12.7       SECOND GENOME          111
12.8       VEDANTA BIOSCIENCES, INC.    112
12.9       FERRING PHARMACEUTICALS   114
12.10     EVELO BIOSCIENCES, INC.         116
12.11     VITHERA PHARMACEUTICALS, INC.       118
12.12     BIOMX  119
12.13     LNC THERAPEUTICS     121
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

13          APPENDIX          122

 

LIST OF TABLES

TABLE 1             HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2027 (USD MILLION)          38
TABLE 2             HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION,
2021–2027 (USD MILLION)          39
TABLE 3             NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY 2021–2027 (USD MILLION)             39
TABLE 4             HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION,
2021–2027 (USD MILLION)          40
TABLE 5             NORTH AMERICA: PREBIOTICS MARKET, BY COUNTRY 2021–2027 (USD MILLION)              41
TABLE 6             HUMAN MICROBIOME MARKET FOR FOODS, BY REGION,
2021–2027 (USD MILLION)          41
TABLE 7             NORTH AMERICA: HUMAN MICROBIOME MARKET FOR FOODS,
BY COUNTRY 2021–2027 (USD MILLION)             42
TABLE 8             HUMAN MICROBIOME MARKET FOR MEDICAL FOODS, BY REGION,
2021–2027 (USD MILLION)          43
TABLE 9             NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MEDICAL FOODS,
BY COUNTRY 2021–2027 (USD MILLION)             43
TABLE 10           HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION,
2019–2027 (USD MILLION)          44
TABLE 11           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS,
BY COUNTRY 2019–2027 (USD MILLION)             44
TABLE 12           HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION,
2021–2027 (USD MILLION)          45
TABLE 13           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY 2021–2027 (USD MILLION)      46
TABLE 14           HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2027 (USD MILLION)   48
TABLE 15           HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION,
2019–2027 (USD MILLION)          49
TABLE 16           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS,
BY COUNTRY, 2019–2027 (USD MILLION)            50
TABLE 17           HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION,
2019–2027 (USD MILLION)          51
TABLE 18          NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2027 (USD MILLION)          51
TABLE 19           HUMAN MICROBIOME MARKET, BY DISEASE, 2019–2027 (USD MILLION)             53
TABLE 20           DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR
INFECTIOUS DISEASES 54
TABLE 21           HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2027 (USD MILLION)          55
TABLE 22           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2027 (USD MILLION)            55
TABLE 23           DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR
INFLAMMATORY DISEASES        56
TABLE 24           HUMAN MICROBIOME MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2019–2027 (USD MILLION)      57
TABLE 25           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2019–2027 (USD MILLION)            57
TABLE 26           DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES              58
TABLE 27           HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS,
BY REGION, 2019-2027 (USD MILLION)   59
TABLE 28           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2019–2027 (USD MILLION)   59
TABLE 29           HUMAN MICROBIOME MARKET FOR CANCER, BY REGION,
2019–2027 (USD MILLION)          60
TABLE 30           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2019–2027 (USD MILLION)          60
TABLE 31           HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION,
2019–2027 (USD MILLION)          61
TABLE 32           NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2019–2027 (USD MILLION)            61
TABLE 33           HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)          63
TABLE 34           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS,
BY REGION, 2017–2024 (USD MILLION)  64
TABLE 35           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2017–2024 (USD MILLION)    64
TABLE 36           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2017–2024 (USD MILLION)          64
TABLE 37           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING,
BY METHOD, 2017–2024 (USD MILLION)              66
TABLE 38           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING,
BY REGION, 2017–2024 (USD MILLION)  66
TABLE 39           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2017–2024 (USD MILLION) 66
TABLE 40           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMICS TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION)             67
TABLE 41           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMICS TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)  67
TABLE 42           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR PROTEOMICS,
BY REGION, 2017–2024 (USD MILLION)  68
TABLE 43           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR PROTEOMICS, BY COUNTRY, 2017–2024 (USD MILLION) 68
TABLE 44           HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR METABOLOMICS,
BY REGION, 2017–2024 (USD MILLION)  69
TABLE 45           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR METABOLOMICS, BY COUNTRY, 2017–2024 (USD MILLION)        69
TABLE 46           HUMAN MICROBIOME MARKET, BY REGION, 2019–2027 (USD MILLION) 72
TABLE 47           HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY REGION,
2017–2024 (USD MILLION)          72
TABLE 48           EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2019–2027 (USD MILLION)          75
TABLE 49           EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION,
2019–2027 (USD MILLION)          75
TABLE 50           EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2019–2027 (USD MILLION)              75
TABLE 51           EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)          76
TABLE 52           EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2017–2024 (USD MILLION)             76
TABLE 53           NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2019–2027 (USD MILLION)          77
TABLE 54           NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2019–2027 (USD MILLION)          77
TABLE 55           NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2019–2027 (USD MILLION)          78
TABLE 56           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION)    78
TABLE 57           NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014–2021 (USD MILLION)             78
TABLE 58           US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2027 (USD MILLION)   79
TABLE 59           US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2027 (USD MILLION)              80
TABLE 60           US: HUMAN MICROBIOME MARKET, BY DISEASE, 2019–2027 (USD MILLION)       80
TABLE 61           US: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)      80
TABLE 62           US: HUMAN MICROBIOME RESEARCH SPENDING FOR GENOMICS, BY TYPE,
2014–2021 (USD MILLION)          81
TABLE 63           INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018         82
TABLE 64           CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2019–2027 (USD MILLION)          82
TABLE 65           CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2019–2027 (USD MILLION)          83
TABLE 66           CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2019–2027 (USD MILLION)              83
TABLE 67           CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)          83
TABLE 68           CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014–2021 (USD MILLION)             84
TABLE 69           ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT,
2019–2027 (USD MILLION)          87
TABLE 70           ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION,
2019–2027 (USD MILLION)          87
TABLE 71           ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE,
2019–2027 (USD MILLION)          87
TABLE 72           ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET,
BY TECHNOLOGY, 2017–2024 (USD MILLION)    88
TABLE 73           ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014–2021 (USD MILLION)             88
TABLE 74           ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2027 (USD MILLION)              89
TABLE 75           ROW: HUMAN MICROBIOME MARKET, BY APPLICATION,
2019–2027 (USD MILLION)          90
TABLE 76           ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2019–2027 (USD MILLION)   90
TABLE 77           ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)          90
TABLE 78           ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS,
BY TYPE, 2014–2021 (USD MILLION)       91
TABLE 79           AGREEMENTS AND PARTNERSHIPS, 2016–2019  94
TABLE 80           ACQUISITIONS AND MERGERS 2016–2019           95
TABLE 81           PRODUCT LAUNCHES, 2016–2019           96
TABLE 82           EXPANSIONS, 2016–2019 96

LIST OF FIGURES

FIGURE 1            RESEARCH DESIGN        19
FIGURE 2            PRIMARY SOURCES        21
FIGURE 3            BOTTOM-UP APPROACH           23
FIGURE 4            TOP DOWN APPROACH              23
FIGURE 5            DATA TRIANGULATION METHODOLOGY          24
FIGURE 6            HUMAN MICROBIOME MARKET SHARE, BY PRODUCT, 2022       25
FIGURE 7            HUMAN MICROBIOME MARKET, BY APPLICATION, 2022             26
FIGURE 8            GEOGRAPHICAL SNAPSHOT OF THE HUMAN MICROBIOME MARKET    26
FIGURE 9            INCREASING FOCUS ON HUMAN MICROBIOME THERAPY DEVELOPMENT TO DRIVE THE GROWTH OF THIS MARKET            28
FIGURE 10          PROBIOTICS DOMINATED THE HUMAN MICROBIOME PRODUCTS MARKET IN 2022              29
FIGURE 11          INFECTIOUS DISEASES TO REGISTER THE HIGHEST GROWTH IN THE MARKET,
BY DISEASE, DURING THE FORECAST PERIOD   31
FIGURE 12          HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES        32
FIGURE 13          NUMBER OF MICROBIOME MODULATORS IN ACTIVE DEVELOPMENT,
BY YEAR, 2011–2017       45
FIGURE 14          GEOGRAPHIC SNAPSHOT: NORTH AMERICA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD           71
FIGURE 15          EUROPE TO DOMINATE THE HUMAN MICROBIOME MARKET DURING THE PERIOD OF 2024 TO 2027             74
FIGURE 16          ASIA PACIFIC HUMAN MICROBIOME MARKET: SNAPSHOT         86
FIGURE 17          HUMAN MICROBIOME MARKET (GLOBAL), COMPETITIVE LEADERSHIP
MAPPING, 2018 93
FIGURE 18          SERES THERAPEUTICS: COMPANY SNAPSHOT (2018)     100
FIGURE 19          4D PHARMA PLC: COMPANY SNAPSHOT (2018) 102
FIGURE 20          E.I. DU PONT DE NEMOURS AND COMPANY: COMPANY SNAPSHOT (2018)         106
FIGURE 21          SYNLOGIC: COMPANY SNAPSHOT (2018)            109

FIGURE 22          EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2018)             116

 

当レポートのプレスリリースは発行されておりません。